Flualprazolam
Viewing r1 — May 8, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Flualprazolam is a synthetic depressant of the benzodiazepine class. It is the 2'-fluoro structural analog of alprazolam, distinguished by greater potency and a longer duration of action.[1] Flualprazolam is a positive allosteric modulator of the GABA-A, producing its effects by amplifying the brain's primary inhibitory signalling system.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
alprazolam, all benzodiazepines, alcohol +4 morealprazolam, all benzodiazepines, alcohol, barbiturates, zolpidem, zopiclone, GHB show less
Synthesized in 1976 as one of dozens of triazolobenzodiazepine candidates in a broad patent, flualprazolam was never selected for clinical development.[2] It appeared on unregulated drug markets in 2018 and within two years became one of the most frequently detected designer benzodiazepines in forensic casework worldwide.[3] It is now US Schedule I[4] and internationally controlled under the 1971 Convention.
Subjective effects include anxiolysis, sedation, muscle relaxation, cognitive suppression, and anterograde amnesia. The experience is one of rapid, enveloping calm — anxiety dissolves into heavy sedation and emotional suppression, while memory formation progressively shuts down, leaving partial or total blackouts at moderate doses. Delusions of sobriety, disinhibition, and motor incoordination are characteristic unsought effects.
Flualprazolam produces physical dependence with repeated use, and withdrawal carries seizure risk; no lethal dose has been established, but deaths are well-documented in forensic literature. The primary mortality mechanism is synergistic respiratory depression when combined with opioids — present in 83% of postmortem cases.[5] No controlled human studies have been conducted; the current understanding rests on forensic casework, animal data, and structural analogy to alprazolam.
History[edit]
Discovery
Flualprazolam was first prepared in 1976 by J.B. Hester Jr. during a systematic survey of triazolo-fused benzodiazepine structures, covered by US Patent 3987052A.[2] The patent described a broad family of compounds from which alprazolam and triazolam were advanced to clinical trials. Flualprazolam — the 2'-fluoro variant of alprazolam — was catalogued but never pursued for therapeutic development by any manufacturer.
Emergence as a novel psychoactive substance
Flualprazolam surfaced on European drug markets in 2018, flagged through the EMCDDA Early Warning System. Its first published forensic identification came in 2019, when it was detected in an anesthesia-robbery case in China.[6] That same year, the Oregon Poison Center documented six adolescent intoxications in a single week, all traced to counterfeit alprazolam tablets.[7] By early 2020, a single US forensic laboratory had confirmed flualprazolam in 197 blood samples,[5] and the UNODC reported it as one of the two most frequently detected designer benzodiazepines globally.[3]
Scheduling and market shift
The WHO recommended international control in December 2019, and the Commission on Narcotic Drugs adopted Schedule IV placement under the 1971 Convention in 2020.[8] The United Kingdom classified it as Class C in August 2021,[9] and the US DEA imposed temporary Schedule I in December 2022,[10] made permanent in April 2026.[4] Following scheduling, bromazolam increasingly replaced flualprazolam as the dominant designer benzodiazepine in some forensic jurisdictions.[11]
The name flualprazolam is a pharmaceutical-style contraction: flu- denotes the fluorine substitution, appended to alprazolam, the parent compound. It circulated widely as counterfeit Xanax tablets pressed to mimic pharmaceutical alprazolam, detected across multiple continents including New Zealand[12] and in UNODC-confirmed falsified tablets containing both flualprazolam and flubromazolam.[13]
Chemistry[edit]
Structure
Flualprazolam is a triazolobenzodiazepine — a 1,4-benzodiazepine with a 1,2,4-triazole ring fused at the [4,3-a] position. This structural motif is shared with alprazolam and triazolam.[17] The triazole fusion increases metabolic stability relative to non-fused benzodiazepines.
The sole structural difference from alprazolam is a fluorine atom at the ortho position of the pendant phenyl ring. This single substitution — replacing hydrogen with fluorine — increases lipophilicity and resistance to oxidative metabolism, approximately doubling the volume of distribution and half-life in rat models.[1]
Molecular properties
| Molecular formula | C₁₇H₁₂ClFN₄ |
| Molecular weight | 326.8 g/mol |
The molecule contains four nitrogen atoms across the benzodiazepine and triazole rings. The 8-chloro substituent on the A-ring and the 1-methyl group on the triazole are conserved from alprazolam. The ortho-fluorine introduces an electronegative, lipophilic group that drives the pharmacokinetic differences between the two compounds.
Stereochemistry
Flualprazolam lacks a conventional chirality centre and is not encountered as distinct enantiomers.
Physical properties
| Appearance | Off-white powder |
| Melting point | 203–204 °C |
| Solubility | Soluble in dichloromethane and methanol; partially soluble in water |
No published data on salt forms, partition coefficient, or long-term storage stability have been identified.citation needed
Pharmacology[edit]
Mechanism of action
Flualprazolam binds at the benzodiazepine site of the GABA-A — a chloride-conducting ion channel that mediates the brain's primary inhibitory signalling. When flualprazolam occupies this site, it amplifies the effect of GABA already present at the receptor, increasing the frequency of chloride channel openings and strengthening inhibitory transmission throughout the brain. The result is dose-dependent sedation, anxiety relief, muscle relaxation, suppression of seizure activity, and impairment of memory formation.
No direct binding-affinity measurements have been published. Computational modelling classifies flualprazolam as potent relative to other designer benzodiazepines,[18] and forensic data confirm pharmacological effects at blood concentrations as low as 4–15 ng/mL.[19][20]
Pharmacokinetics
No controlled human pharmacokinetic studies exist. The available data combine a single clinical case, forensic case series, and a rat pharmacokinetic study.
Absorption
Oral onset is reported at 20–40 minutes, consistent with the triazolobenzodiazepine class. No human bioavailability data have been published.
Distribution and elimination
In rats, flualprazolam showed approximately twice the volume of distribution and twice the half-life of alprazolam at equivalent doses.[1] Since alprazolam has a human half-life of roughly 11 hours, flualprazolam's human half-life may be on the order of 20 hours or longer — though species extrapolation carries substantial uncertainty.inferred
The detection window in a rabbit model was approximately 36 hours.[21]
Metabolism
Flualprazolam is broken down primarily through hydroxylation in the liver. The main metabolites — α-hydroxy flualprazolam and 4-hydroxy flualprazolam — are subsequently conjugated and excreted in urine.[22] The glucuronide conjugates are far more abundant than the parent compound in urine, making them the preferred targets for drug testing.[22]
Genetic differences in liver enzyme activity may substantially alter how quickly individuals process the drug, though this has not been systematically studied for designer benzodiazepines.[22][23]
Forensic detection
Standard hospital drug screens for benzodiazepines will flag flualprazolam, but standard confirmatory testing panels often fail to identify it specifically — in one study, it was found in 11 of 35 specimens initially classified as false-positive benzodiazepine screens.[24]
Neuroscience[edit]
Where it acts
Flualprazolam strengthens GABA-mediated inhibition across widespread brain circuits.inferred In the prefrontal cortex, this dampens excitability and slows information processing — the neural basis of the cognitive blunting and sedation users report. In the amygdala, reduced reactivity to threat underlies the anxiolytic effect. In the hippocampus, suppression of long-term potentiation disrupts memory consolidation, producing the anterograde amnesia that defines moderate-to-high dose experiences.
Why it matters
The reinforcing properties of benzodiazepines arise from an indirect mechanism: suppression of inhibitory interneurons in the ventral tegmental area disinhibits dopamine release in the reward circuit, driving the compulsive redosing pattern reported with potent designer benzodiazepines. The characteristic delusions of sobriety — users believing they are functionally normal while objectively impaired — can be understood through predictive processing: enhanced inhibitory signalling raises the weight of the brain's internal expectations, suppressing the error signals that would normally flag impairment.[19]
Several fundamental questions about flualprazolam remain unanswered. Whether the ortho-fluorine substitution alters selectivity among GABA-A subtypes — which would predict differences in the balance of sedation, anxiolysis, and amnesia relative to alprazolam — has not been tested. The true human half-life remains unknown; the rat estimate of roughly double alprazolam's[1] awaits human confirmation. The extended aftereffects reported by users (6–24 hours) exceed simple half-life predictions, raising the possibility of active metabolites or slow redistribution from tissue stores.
Subjective Effects[edit]
The flualprazolam experience centres on a rapid dissolution of anxiety into deep, heavy sedation. At threshold doses, anxiolysis and mild muscle relaxation predominate; as dose increases, cognitive function narrows, emotional responsiveness flattens, and anterograde amnesia becomes the defining feature — users frequently report total blackouts spanning hours. Set and setting modulate the character substantially: anxious individuals may experience pronounced euphoria from anxiety suppression alone, while non-anxious users often report undifferentiated sedation.
Relative to alprazolam, flualprazolam produces a comparable subjective profile at lower absolute doses, with aftereffects that persist noticeably longer. Among designer benzodiazepines, it occupies a potency tier alongside clonazolam and flubromazolam, distinguished primarily by its triazolobenzodiazepine structure and extended duration rather than qualitatively different effects.
Effect Grid
Clear anxiolysis progressing to moderate sedation defines this range. Emotional suppression becomes apparent — a blunting of both positive and negative affect. Thought deceleration is pronounced, with analysis suppression reducing the capacity for complex reasoning. Anterograde amnesia becomes significant: users may have incomplete or absent recall of events during the experience.
Motor control impairment is now obvious — unsteady gait, slurred speech, and impaired coordination are characteristic. Muscle relaxation is substantial. Dizziness may occur, particularly on standing.
Delusions of sobriety often begin at this dose level — users may perceive themselves as functionally normal despite objectively measurable impairment. Compulsive redosing urge is a significant risk, as amnestic effects cause users to forget they have already dosed. Disinhibition may lead to uncharacteristic behaviour.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Vestibular distortion · Visual haze / noise · Visual processing suppression
Physical fatigue · Dizziness · Body high · Nystagmus (eye wobbles) · Breathing alteration · Insomnia · Sexual arousal suppression · Pain suppression · Heart rate perception changes · Yawning · Tactile euphoria · Sexual arousal enhancement · Dry mouth · Headache · Laughter fits · Nausea · Nausea suppression · Appetite enhancement · Restlessness · Vomiting · Seizure threshold reduction · Bodily dissociation
Nystagmus (eye wobbles) · Breathing alteration · Insomnia · Sexual arousal suppression · Pain suppression · Heart rate perception changes · Yawning · Tactile euphoria · Sexual arousal enhancement · Dry mouth · Headache · Laughter fits · Nausea · Nausea suppression · Appetite enhancement · Restlessness · Vomiting · Bodily dissociation
Cognitive fatigue · Focus suppression · Information processing suppression · Thought deceleration · Memory fragmentation · Motivation suppression · Cognitive euphoria · Confusion · Creativity suppression · Language suppression · Suggestibility enhancement · Thought disorganization · Compulsive redosing urge · Humor enhancement · Cognitive dysphoria · Amnesia · Delirium
Thought deceleration · Memory fragmentation · Motivation suppression · Cognitive euphoria · Confusion · Creativity suppression · Language suppression · Thought disorganization · Compulsive redosing urge · Humor enhancement · Cognitive dysphoria · Amnesia · Delirium
Irritability · Anxiety · Dysphoria · Emotional lability · Paranoia
Emotional lability
Craving · Trust enhancement · Communication enhancement · Social disconnection · Emotional susceptibility · Sociability suppression · Ego inflation · Depersonalization · Derealization · Cognitive disconnection
Emotional susceptibility · Sociability suppression · Ego inflation · Depersonalization · Derealization · Cognitive disconnection
Timeline
Subliminal transition begins. First signs of muscle tension release and a faint shift toward calm emerge before overt anxiolysis.
Anxiolysis builds steadily. Mild sedation and warmth emerge alongside the first hints of cognitive slowing and muscle relaxation.
Full anxiolysis, sedation, and amnesia. Motor control impairment, emotional suppression, and disinhibition reach maximum intensity. Delusions of sobriety may mask the degree of impairment.
Sedation dominates as peak intensity levels off. Amnesia continues. Cognitive and motor impairment remain substantial but stable.
Gradual return of baseline cognition. Sedation wanes and motor coordination slowly improves, though impairment may persist longer than subjective awareness suggests.
Residual sedation, cognitive fog, and possible next-day impairment. Memory of the experience may be fragmented or absent.
⚠ Do not drive or operate heavy machinery for at least 24 hours after use — residual impairment may persist beyond subjective awareness of effects.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- moderate
- Tolerance reset
- 21 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- alprazolam · all benzodiazepines · alcohol
Toxicity
Acute toxicity
No lethal dose, therapeutic index, or controlled toxicity data exist for flualprazolam in any species.safety citation needed In the largest clinical case series, six adolescents who ingested counterfeit alprazolam tablets containing flualprazolam experienced sedation, slurred speech, confusion, and mild respiratory depression; all recovered within 6 hours without antidotal treatment.[7]
Forensic death data are extensive. In Sweden and Finland, flualprazolam was detected in 33 deaths and implicated in the cause of death in 13 (39%); decedents were predominantly male (82%) with a median age of 30.[25] In the largest US forensic series, postmortem blood concentrations ranged from 2.0–620 ng/mL (mean 20, median 8.2; n=167).[5] Flualprazolam was among the most frequently implicated designer benzodiazepines in a review of 141 deaths involving the drug class.[26]
Flualprazolam is rarely the sole cause of death. The vast majority of fatalities involve polydrug use. Opioids — predominantly fentanyl — were co-detected in 83% of postmortem cases.[5] Synergistic respiratory depression from benzodiazepine-opioid combinations is the primary mechanism of death.
Organ toxicity
No liver, kidney, or heart toxicity data have been identified for flualprazolam. Benzodiazepines as a class are not typically associated with direct organ damage at pharmacologically relevant doses.
Drug-facilitated crime
Flualprazolam's sub-milligram potency, rapid onset, and powerful amnestic effects have led to its documented use in drug-facilitated sexual assault and robbery.[21][6]
Psychological Risks
Anterograde amnesia is the most prominent psychological effect, documented in clinical cases.[22][9] Users may have no recall of events during intoxication.
Delusions of sobriety represent a major safety hazard. Users may be severely impaired — measurably so on psychomotor testing — while believing themselves functionally normal. Forensic driving data consistently document this disconnect.[19][5]
Disinhibition can manifest as uncharacteristic risk-taking, aggression, or impulsive behaviour, documented at clinical concentrations.[22]
Rebound anxiety occurs upon cessation in regular users and scales with dose, duration of use, and speed of discontinuation.
Tolerance & Dependence
No flualprazolam-specific studies exist; assessments are based on benzodiazepine class pharmacology.inferred
Tolerance to sedative effects develops through changes in GABA-A expression, including receptor internalisation and shifts in subunit composition. Tolerance to anxiolytic effects develops more slowly and may remain incomplete. Flualprazolam's extended half-life[1] may modulate the rate of tolerance development relative to shorter-acting benzodiazepines.inferred
Cross-tolerance is expected with all GABA-A-active substances, including other benzodiazepines, alcohol, barbiturates, and Z-drugs.
Physical dependence produces a withdrawal on cessation: rebound effect anxiety, insomnia, tremor, sweating, perceptual disturbances, and — in severe cases — seizures. Seizure risk is the most dangerous withdrawal complication and requires medically supervised tapering.
Detoxification follows standard protocols: substitution with a long-acting pharmaceutical benzodiazepine (typically diazepam) followed by gradual taper. No flualprazolam-to-diazepam equivalence ratio has been established.[27][28]
Drug Interactions
Opioids (critical)
The most dangerous combination. Synergistic respiratory depression is the primary mechanism of flualprazolam-associated death: opioids were co-detected in 83% of postmortem cases.[5] Flualprazolam was significantly overrepresented in isotonitazene-related overdose deaths.[14][15] This combination carries extreme lethality risk.
Alcohol and other depressants
Synergistic depression of consciousness and breathing is expected with alcohol, other benzodiazepines, barbiturates, Z-drugs, GHB, and gabapentinoids. The UK ACMD specifically identified increased risk of unconsciousness and respiratory depression in these combinations.[9]
CYP3A4 inhibitors
Flualprazolam is metabolised primarily by the liver enzyme CYP3A4.[22] Drugs that inhibit this enzyme — including ketoconazole, itraconazole, clarithromycin, HIV protease inhibitors, and grapefruit juice — are expected to significantly increase flualprazolam blood levels.inferred
CYP3A4 inducers
Drugs that speed up CYP3A4 activity (rifampicin, carbamazepine, phenytoin, St John's Wort) would be expected to accelerate flualprazolam breakdown. In physically dependent users, this could precipitate withdrawal including seizures.[22]inferred
Flumazenil
The benzodiazepine reversal agent flumazenil is expected to reverse flualprazolam's effects. In dependent users, flumazenil can trigger acute withdrawal including seizures.inferred
Contraindications
No flualprazolam-specific data exist. The following are inferred from benzodiazepine class pharmacologyinferred:
Absolute:
- Concurrent opioid use — synergistic respiratory depression; 83% of postmortem cases involved opioids[5]
- Severe breathing disorders — GABA-A activation depresses respiratory drive
- Myasthenia gravis — muscle-relaxant effect may worsen neuromuscular weakness
- Acute narrow-angle glaucoma — benzodiazepine class contraindication
Relative:
- Liver disease — impaired metabolism risks drug accumulation
- Concurrent CYP3A4 inhibitors — risk of dangerously elevated blood levels
- History of substance use disorder — inherent reinforcing properties
- Pregnancy — benzodiazepine class risk; no reproductive data specific to flualprazolam
- Elderly — increased sensitivity, fall risk, prolonged elimination
- Sleep apnoea — respiratory depression may worsen apnoea
Harm Reduction[edit]
Forms & Identification
Flualprazolam is active at sub-milligram doses, making accurate dosing without analytical equipment essentially impossible with raw powder. Counterfeit tablets vary widely in content — some contain flualprazolam alone, others contain mixtures of designer benzodiazepines or entirely different compounds. A tablet that looks identical to pharmaceutical Xanax may contain a substance with a different potency, duration, and risk profile entirely.
Fentanyl test strips and reagent kits cannot distinguish between different benzodiazepines. Laboratory-grade analysis — such as services offered by drug-checking programmes — is the only reliable way to confirm what a tablet actually contains.
Guidelines
- Never dose from raw powder without a milligram-precision scale (0.001 g). Even with one, sub-milligram precision is unreliable — volumetric dosing (dissolving a known quantity in a measured volume of solvent) is strongly preferred.
- Start with the lowest available dose and wait at least 2 hours before considering redosing. Onset can be delayed, and the long half-life means effects accumulate.
- Store all remaining doses out of reach before the first dose takes effect. Amnesia-driven redosing is the most common pathway to dangerous intoxication.
- Do not combine with opioids, alcohol, or other depressants under any circumstances.
- Do not drive or operate machinery. Impairment persists far longer than users perceive.
- Tell a trusted person what you have taken, how much, and when.
Set & Setting
The defining hazard of flualprazolam use is the combination of powerful amnesia and delusions of sobriety. Users consistently overestimate their functional capacity while intoxicated. A safe environment means one where impaired judgement cannot lead to driving, dangerous decisions, or unsupervised access to more drugs.
The presence of a sober companion who can intervene if redosing begins is the single most important environmental safeguard — compulsive redosing during amnesia is a frequently reported pattern with potent designer benzodiazepines.
Aftercare & integration. Flualprazolam's extended half-life means residual sedation, impaired coordination, and cognitive fog can persist well beyond the subjective experience. Allow a full day for recovery before driving or making important decisions.
Memory gaps are common and can be disorienting. If a trusted companion was present, ask them to fill in the timeline. Avoid using alcohol or other sedatives during the recovery window — the drug is still being cleared and stacking depressants extends the risk period.
If use was a response to anxiety or distress, the period after the drug wears off is an opportunity to assess that pattern honestly. Benzodiazepine anxiolysis provides temporary relief but reinforces avoidance of the underlying problem. Professional support for anxiety management can reduce the drive toward repeated self-medication.
Recovery & Support
Physical dependence on flualprazolam or other designer benzodiazepines requires medical management. Do not stop abruptly — benzodiazepine withdrawal can cause seizures and is potentially life-threatening. A supervised taper under medical guidance, typically using diazepam substitution, is the standard approach.[27][28]
Peer support communities familiar with benzodiazepine withdrawal (such as BenzoBuddies or equivalent local services) can provide practical guidance alongside clinical care. Recovery timelines for benzodiazepine dependence are often longer than expected — protracted withdrawal symptoms including anxiety, insomnia, and sensory sensitivity may persist for weeks to months. This is a recognised medical phenomenon, not a personal failing.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency:
- Breathing becomes slow, shallow, or stops
- Lips or fingertips turn blue
- Person cannot be woken by loud voice or sternal rub
- Seizure activity (in users who may be in withdrawal)
Immediate steps:
- Call emergency services immediately if breathing is compromised or the person is unresponsive.
- Place the person in the recovery position (on their side, airway open).
- Do not induce vomiting.
- If opioid co-ingestion is suspected, administer naloxone — it will not reverse benzodiazepine effects but may reverse opioid respiratory depression.
- Monitor breathing continuously until help arrives.
What to tell the dispatcher: Name the substance (flualprazolam or designer benzodiazepine), estimated amount, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution.
Reversal agent: Flumazenil reverses benzodiazepine effects but is rarely administered outside hospital settings. In dependent users it can trigger seizures. Its use is a clinical decision, not a field intervention.
Legal Status[edit]
Flualprazolam is internationally controlled under Schedule IV of the 1971 Convention on Psychotropic Substances, following WHO recommendation in December 2019 and adoption by the Commission on Narcotic Drugs in 2020.[8] It has no approved medical use in any jurisdiction.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International (UN) | Schedule IV, 1971 Convention on Psychotropic Substances | Adopted 2020; binding on all signatory states[8] |
| United States | Schedule I (Controlled Substances Act) | Emergency Schedule I from December 2022;[10] extended July 2025;[29] permanent Schedule I effective 1 April 2026. Co-scheduled with clonazolam, diclazepam, etizolam, and flubromazolam[4] |
| United Kingdom | Class C, Schedule 1 (Misuse of Drugs Act 1971) | Effective 18 August 2021[9] |
| Australia | Controlled substance | 43 detections in Victoria (2018–2022)[30][28] |
| Canada | Controlled (CDSA) | Benzodiazepines as a class are controlled under the Controlled Drugs and Substances Act |
| European Union | Monitored via EU Early Warning System | Monitored by EMCDDA from 2018; individual member state scheduling varies |
| Nordic countries | Controlled (various national laws) | Detected in forensic cases from 2016–2019[25][31] |
| New Zealand | Controlled (Misuse of Drugs Act 1975) | Detected in counterfeit Xanax tablets[12] |
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6] ^abQian Z, Liu C, Huang J, Deng Q, Hua Z (2019) Identification of the designer benzodiazepine 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine (flualprazolam) in an anesthesia robbery case — Forensic Toxicology doi:10.1007/s11419-019-00501-1